Resistance to change has emerged as the biggest barrier (51%) to data innovation in the pharmaceutical industry, while lack of skills is the second most cited barrier (17%). 

The new findings on data-driven innovation and AI in life sciences were released by the Pistoia Alliance in conjunction with CCC (Copyright Clearance Center).  

The research was conducted at the Pistoia Alliance’s annual European conference, held at the Royal Society of Medicine in London. 

“The poll confirms what many of our members are experiencing – that progress depends on people, culture and skills, not just technology,” commented Dr Becky Upton, Pistoia Alliance President. “The goal of digital transformation is to accelerate the development of better treatments and improve patient outcomes. That means we must empower the people behind the science – from researchers to C-suite leaders – with the right skills and mindset to embrace innovation.” 

Agentic AI was identified as the technology expected to have the most impact over the next two to three years by both the Alliance’s recently completed LLM project and a panel of speakers from UK Medicines & Healthcare Products Regulatory Agency (MHRA), AbbVie, AstraZeneca, and Amino Data.  

However, apprehension around AI still remains in the industry, with 39% of respondents citing AI models producing incorrect answers as the biggest concern regarding the technology.  

Reputational risk was the highest concern for companies when building, choosing or using AI technologies (37%), followed by safety (17%).  

Despite these anxieties, 17% said their organisations never or rarely formally assess risks associated with AI use. 

Need to stay ahead of AI regulation

“Companies know that increased AI regulation is on the horizon – in fact, 59% of our respondents expect increased government regulation in the next five years,” commented Neal Dunkinson, Senior Director of Solution Sales at CCC. “Now is the time to embed rigorous AI risk assessments into everyday practice. Events like the Alliance’s conference are key for bridging the gap between pharma and regulators, helping the industry align on shared frameworks that support trustworthy and responsible AI use. By laying these foundations today, organisations can both stay ahead of evolving regulation and safely unlock AI’s potential.” 

The Alliance is seeking investment and support from pharma, technology and other stakeholder organisations in its agentic AI project. The project sets out to define the roles and functions of AI agents in clinical and preclinical settings and establish industry guidelines for how agents should interact and work together.

Diana Spencer, Senior Digital Content Editor, DDW